Xilio boosts liquidity via Gilead/AbbVie deals but flags going-concern, warrants add volatility

Xilio Therapeutics, Inc. (NASDAQ: XLO) - Q2 2025 snapshot

Key points & statistics
* Cash and cash equivalents: $121,551 (thousands) as of June 30, 2025.
* Total assets: $133,813; total liabilities: $126,744; stockholders' equity: $7,069 (all in thousands).
* Collaboration & license revenue (Q2 2025): $8,084 vs $2,357 (Q2 2024). Six months ended June 30, 2025: $11,014 vs $2,357 (2024).
* R&D expense (Q2 2025): $15,330 vs $11,216 (Q2 2024). Six months: $23,596 vs $21,616.
* G&A expense (Q2 2025): $7,120 vs $5,815 (Q2 2024). Six months: $15,635 vs $11,954.
* Loss from operations (Q2 2025): $(14,366); net loss (Q2 2025): $(15,844). Six months net loss: $(29,109) vs $(31,128).
* Net loss per share, basic & diluted: Q2 2025 $(0.16); six months $(0.34).
* Weighted average shares outstanding (basic & diluted): Q2 2025 96,447,672; six months 85,634,094.
* Deferred revenue as of June 30, 2025: $70,910 (Gilead $27,325; AbbVie $43,585).
* Common stock warrant liabilities (fair value, Level 3): $38,550 (Series A $26,440; B $6,830; C $5,280).
* Accumulated deficit: $(412,862).
* Shares outstanding: 51,827,910 (reported August 8, 2025).
* Prefunded warrants outstanding: 92,278,707; total shares reserved for future issuance: 307,587,185.

What's happening inside the company - short, direct
* Xilio is buying time and advancing programs via strategic partnerships: Gilead (IL-12 program) and AbbVie (multi-program collaboration) supplied upfront cash and equity that materially improved liquidity in H1 2025.
* Management is spending heavily to progress clinical programs: vilastobart (CTLA‑4) and XTX301 (IL‑12) are the lead programs; XTX501 and masked T‑cell engager programs are moving in IND‑enabling or preclinical work.
* Financing activity in June 2025 (follow‑on offering of prefunded warrants + common stock warrants) delivered initial gross proceeds of $50.0M and net proceeds of ~$47.0M; associated warrant liabilities ($38.55M) introduce earnings volatility through fair‑value remeasurement.
* Company states cash runway "through the end of Q3 2026" but management explicitly flags substantial doubt about going concern - additional capital likely required.

Positive aspects from the income statement
* Collaboration & license revenue increased sharply (Q2 +$5.7M vs prior year quarter) driven by AbbVie and continued Gilead recognition - demonstrates deal monetization of R&D.
* Deferred revenue balance ($70.9M) supports near‑term revenue recognition tied to contracted services and licenses (creates predictable cash-to-revenue conversion as services are delivered).
* Operating cash flow improved: net cash provided by operating activities for six months was $14,501 - driven largely by deferred revenue additions from upfront payments.
* Financing in H1 2025 generated $52,194 of cash (financing activities), materially strengthening the balance sheet vs Dec 31, 2024 cash of $55,291.

Negative aspects from the income statement
* Company remains loss‑making: six‑month net loss $(29.1M) (YTD 2025) and accumulated deficit $(412.9M) - continuing cash burn is expected.
* R&D and G&A both increased year‑over‑year: Q2 total operating expense rose to $22.45M from $17.06M - spending is rising while product revenues are still limited to collaboration recognition.
* Net loss per share volatility: large change in weighted average shares (dilution) - Q2 share count jumped to 96.4M (impacting per‑share metrics).
* Significant liability volatility from warrant accounting: $38.55M classified as liabilities and remeasured to fair value creates earnings swings and $2.3M of issuance costs were charged to other expense in Q2.
* Equity base is thin relative to obligations: stockholders' equity only $7.069M as of June 30, 2025 - limited cushion against liabilities and ongoing losses.

Liquidity, financing and material risks to watch
* Cash runway: management projects cash into Q3 2026, but that is conditional and management warns substantial doubt about going concern - additional capital or milestone/cash exercise of warrants required.
* Dilution risk: 92.3M prefunded warrants outstanding plus common warrant pools (200M+ reserved) create potential for heavy dilution if exercised; Series B & C cash exercise could add up to ~$100M in gross proceeds if exercised, but exercise is uncertain.
* Nasdaq compliance: bid price was below $1.00 for >30 business days - company has until Oct 1, 2025 to regain compliance (or pursue transfer to Nasdaq Capital Market); delisting risk could impact liquidity and access to capital.
* Concentration of collaboration revenue: near‑term revenue and upside depend on AbbVie and Gilead milestones and payments - these are large but largely contingent and currently excluded from transaction price as "fully constrained."

What to monitor next (practical checklist)
* Clinical readouts and milestones for vilastobart and XTX301 (data and timelines).
* Execution of AbbVie collaboration milestones and any option exercises that would generate revenue or upfront fees.
* Warrant exercise activity and updates on the potential $100M cash exercise scenario (Series B/C).
* Cash balance updates and any announced equity/debt financing or milestone receipts that would address the going‑concern warning.
* Nasdaq bid price compliance progress and any management plans (reverse split, transfer to Nasdaq Capital Market, etc.).

Bottom line
Xilio (NASDAQ: XLO) has converted strategic partnerships into meaningful near‑term cash and deferred revenue, which materially improved liquidity in H1 2025. That said, the company remains loss‑making, is still burning cash to advance multiple clinical and preclinical programs, carries large warrant liabilities that produce earnings volatility, and explicitly discloses substantial doubt about going concern beyond its stated runway. The story is execution‑dependent: clinical progress and favorable partner/milestone or warrant exercise outcomes are the clear drivers that would reduce financing risk and valuation uncertainty. Keep an eye on program data, AbbVie/Gilead milestone developments, warrant exercise updates, and Nasdaq compliance progress.